Related Experiment Video

Updated: May 15, 2026

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

Immunotherapy for head and neck cancer patients: shifting the balance

Annelies W Turksma1, Boudewijn Jm Braakhuis, Elisabeth Bloemena

  • 1VU University Medical Center - Cancer Center Amsterdam, Department of Pathology 2.26, de Boelelaan 1117, NL-1081 HV Amsterdam, The Netherlands.

Immunotherapy
|December 22, 2012
PubMed

Insights

Immunotherapy offers new hope for head and neck squamous cell carcinoma (HNSCC) patients, especially those with increasing HPV-related HNSCC. Treatment selection depends on tumor and patient immune status for optimal outcomes.

Area of Science:

  • Oncology
  • Immunology
  • Virology

Background:

  • Head and neck squamous cell carcinoma (HNSCC) is a prevalent cancer with a historically low 5-year survival rate.
  • Limited therapeutic advancements necessitate novel treatment strategies for HNSCC.
  • A subset of HNSCC cases are associated with viral infections, notably human papillomavirus (HPV).

Purpose of the Study:

  • To explore the potential of immunotherapy for head and neck cancer patients.
  • To identify challenges and opportunities in applying immunotherapy to HNSCC.
  • To discuss the distinct characteristics of HPV-related HNSCC and its implications for treatment.

Main Methods:

  • Review of current understanding of HNSCC and viral involvement.
  • Analysis of viral antigens as targets for immunotherapy.
  • Consideration of patient and tumor factors in treatment selection.

Main Results:

  • Virus-induced tumors, particularly HPV-related HNSCC, present unique targets for immunotherapy.
  • The increasing incidence of HPV-related HNSCC represents a distinct clinical entity.
  • Viral antigens are viable targets for immunotherapeutic interventions.

Conclusions:

  • Immunotherapy holds promise for improving outcomes in HNSCC.
  • Effective immunotherapy requires careful consideration of the tumor's HPV status and the patient's immune profile.
  • Personalized immunotherapy approaches are crucial for maximizing treatment efficacy in HNSCC.

More Related Videos

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...